The field of peptide therapy has reached extraordinary scientific maturity over the last two decades, yet it continues to clash with a fundamental obstacle that traditional pharmaceutical chemistry struggles to circumvent: the stability of peptides in biologically aggressive environments. Peptide molecules, regardless of their therapeutic potency, are subject to rapid enzymatic degradation, thermal instability, and an extremely narrow bioavailability window. The human body is, from this perspective, a paradoxical environment: the enzymatic system that should be the theater of the drug's action is also the primary agent responsible for its premature destruction. This is where silk fibroin enters as an engineered biomaterial — not as a passive carrier, but as an active molecular architecture capable of negotiating with the host's biology the rhythm and distribution of the therapeutic payload.
Protein structure and compatibility with bioactive peptides
Fibroin presents a structural hierarchy that lends itself with an almost engineered coherence to the encapsulation of bioactive molecules. Its heavy chain, composed mainly of repetitive glycine-alanine-glycine-serine-glycine-alanine sequences, forms beta lamellae that pack into highly ordered antiparallel configurations. This architecture is not rigid in an absolute sense: the presence of amorphous interdomain sequences, rich in hydrophilic and flexible residues, creates spatial niches where peptides can be physically entrapped through non-covalent interactions of hydrophobic, electrostatic, and hydrogen-bonding nature. The ability to simultaneously host peptides with different chemical characteristics, without denaturing them, is a rare property among available biomaterials and distinguishes fibroin from synthetic polymers or lipid matrices.
The most relevant aspect from an engineering standpoint is that the secondary structure of fibroin can be modulated before, during, and after matrix formation. The transition from silk I to silk II conformation — that is, from alpha-helix and parallel beta-sheet to crystalline antiparallel beta-sheet — is governable through physicochemical parameters such as salt concentration, pH, relative humidity, drying temperature, and alcoholic vapor treatment. Each structural configuration corresponds to a different release kinetic profile, effectively creating a modular system that requires no aggressive chemical modifications to the peptide being carried.
Molecular mechanisms of peptide loading and retention
Loading a therapeutic peptide into a fibroin matrix can occur through two distinct philosophies, both with precise implications for release kinetics. In physical loading, the peptide is introduced into the aqueous fibroin solution before gelation or drying, distributing itself within the amorphous regions of the matrix during the sol-gel transition. The peptide remains entrapped by the formation of the surrounding crystalline network, but its mobility depends critically on molecular size, net charge, and hydropathic affinity with the protein chain domains.
In co-assembly loading, instead, advantage is taken of fibroin's capacity to form supramolecular structures in the presence of amphiphilic or charged molecules. Some therapeutic peptides, particularly those with alternating sequences of polar and apolar residues, act as templates for the fibroin structure itself, inducing the formation of beta-sheet domains around their own structure. This mode of interaction generates systems in which the peptide is not simply included in the matrix, but is an integral part of its molecular architecture. Release therefore occurs not through simple diffusion, but through progressive structural reorganization of the matrix in response to specific hydrolytic or enzymatic conditions.
Nanoparticulate and microparticulate systems
One of the most fertile directions in applied research is the formulation of fibroin into particulate systems of controlled dimensions. Fibroin nanoparticles, with a diameter typically ranging between 50 and 400 nanometers, offer an extremely high surface-to-volume ratio and the ability to cross biological barriers that remain inaccessible to macroscopic systems. Preparation generally occurs through desolvation of the aqueous fibroin solution in the presence of the peptide, followed by thermal or chemical crosslinking to stabilize the particle.
The key advantage of these systems is twofold. On one hand, the small size facilitates cellular uptake by endocytosis and distribution within the target tissue through blood transcytosis transport mechanisms. On the other, the nanoparticle surface can be functionalized with targeting ligands — antibodies, aptamers, tissue homing peptides — that direct the system toward specific cell populations. In this scheme, fibroin is not only the peptide's protection, but the means that delivers it where it is needed, reducing systemic exposure and concentrating the pharmacological effect at the site of action.
Microparticles, with dimensions in the 1–100 micrometer range, find application instead in contexts where prolonged local release is the priority: subcutaneous implants, matrices for tissue regeneration, intra-articular systems for chronic pain therapy. In these formats, the density of the fibroin crystalline network and the wall thickness of the particle become the dominant engineering parameters for calibrating erosion kinetics and the release profile over time.
Control of release through crystallinity and crosslinking
The crystallinity of fibroin is the structural parameter with the greatest impact on matrix permeability and therefore on the rate of peptide release. A high degree of crystallinity — achievable through methanol or acetone vapor treatment — produces matrices with low water permeability, slow enzymatic degradation, and prolonged peptide release on a timescale of weeks or months. A low degree of crystallinity, obtained by maintaining fibroin in a predominantly amorphous state through rapid lyophilization or low-temperature drying, produces systems that rehydrate and degrade more quickly, with a more immediate release.
Chemical crosslinking adds a further level of control. Bifunctional agents such as genistein, glutaraldehyde at low concentrations, or carbodiimide derivatives allow the creation of inter-chain covalent bonds that stiffen the matrix without significantly altering the biocompatibility of the system. The main challenge of this approach is the selectivity of the reaction: the same amino acid residues that participate in crosslinking — lysines, tyrosines, seric residues — may also be present in the peptide to be carried, creating the risk of unwanted chemical modifications to the drug during matrix preparation. Resolving this problem passes through the choice of chemoselective crosslinking methodologies or through temporary protection of the peptide's reactive groups.
Conformational stability of peptides within the matrix environment
One of the least explored yet most promising aspects of recent literature concerns fibroin's capacity to exert an active stabilizing effect on the conformation of the encapsulated peptide. Spectroscopic studies conducted with Fourier-transform infrared spectroscopy and attenuated reflectance circular dichroism have demonstrated that peptides with an intrinsic tendency toward aggregation or thermal denaturation show greater structural resistance when incorporated into a fibroin matrix compared to their solute form.
This effect is attributed to several concurrent mechanisms. Spatial confinement within the amorphous niches of the matrix physically limits the recruitment of neighboring molecules and the formation of intermolecular aggregates. The low water activity environment in the dry or partially dry matrix slows hydrolytic processes and reduces the conformational mobility of the most labile peptide segments. Non-covalent interactions with the fibroin chain — in particular hydrogen bonding with the carbonyl groups of the protein's peptide backbone — can stabilize helical or sheet structures of the therapeutic peptide that would otherwise not persist in aqueous solution.
Enzymatic degradability as a tool for activated release
A particularly elegant paradigm is that of enzymatically activated release, in which the fibroin matrix does not erode through simple passive hydrolysis but responds to the presence of specific proteases in the tissue microenvironment. Fibroin is degraded by proteases such as serine protease, collagenase, and various cathepsins, all present at significantly elevated concentrations in pathological contexts such as tumors, chronic inflammatory sites, and ischemic tissues. In these environments, the rate of matrix degradation accelerates precisely where drug concentration would be most useful, creating an implicit molecular feedback system.
This property transforms fibroin from a simple excipient into a sensorially responsive system, capable of calibrating the release of the therapeutic peptide as a function of the biological state of the surrounding tissue. Engineering this behavior involves selecting the protein sequence — matrices rich in fibroin light chain degrade more rapidly than those dominated by the heavy chain — and modulating crystallinity, which exposes or protects enzymatic cleavage sites in the amorphous regions of the protein.
Integration with surface engineering approaches for active targeting
The therapeutic efficacy of a peptide delivery system depends not only on the kinetic profile of release, but also on the system's ability to localize near the target tissue. The outer surface of fibroin nanoparticles is chemically accessible and can be modified through selective conjugation reactions without altering the mechanical and release properties of the matrix core. The presence of free amino groups on the side chains of surface-exposed lysines, and of carboxyl groups on aspartic and glutamic acid residues, provides reactive handles for the conjugation of targeting ligands through EDC/NHS chemistry or aqueous-condition click chemistry.
The most studied ligands in this context are RGD peptides for targeting integrins overexpressed in actively proliferating tumor cells, anti-EpCAM antibodies for targeting neoplastic epithelial cells, and cell-penetrating peptides such as TAT and penetratin to facilitate intracellular internalization of the system. The combination of functionalized surface and stabilizing fibroin core creates dual-function systems — they find the target and then deliver the peptide with controlled kinetics — representing the most advanced frontier of protein-based nanomedicine for peptide therapeutics.
Clinical prospects and still open technical limitations
The clinical translation of fibroin-based peptide systems still encounters some technical barriers that research is addressing with growing urgency. The first concerns the standardization of raw material: fibroin extracted from Bombyx mori varies in composition, molecular weight, and degree of degumming depending on rearing conditions, season, and extraction process. This variability is reflected in mechanical and pharmacokinetic properties that are not perfectly reproducible from batch to batch — a critical requirement for regulatory approval.
The second barrier concerns production scale. Fibroin nanoformulation technologies developed in the laboratory — desolvation, microfluidics, electrospray — have not yet been definitively transferred to industrial processes with acceptable yields and costs compatible with commercial pharmaceutical development. The third barrier, more fundamental, is the complete understanding of residual immunogenicity mechanisms: although degummed fibroin shows excellent biocompatibility in the vast majority of animal models and human tissue tests, the presence of minor protein contaminants can generate variable immune responses in sensitized individuals. Resolving these questions — which do not invalidate the platform's potential but rather condition its realization into accessible and safe therapies — is the task that will define the next decade of research on this biomaterial.
